Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ramin Zabihi

Gastroenterology Mission Viejo, CA Medical Doctor

NPI 1508867193 CMS profile 113642

26800 Crown Valley Parkway, Suite 308, Mission Viejo, CA 92691

Open in the dashboard

General payments

$4,535

209 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ramin Zabihi of Mission Viejo, CA is reported in the CMS Open Payments database as having received $4,535 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,252 50
2024 General $762 35
2023 General $541 28
2022 General $568 22
2021 General $635 31
2020 General $304 15
2019 General $474 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramin Zabihi
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ramin Zabihi were reported at $1,252. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ramin Zabihi Gastroenterology median Middle half National median
2019 $474 $417 $126–$1,100 $163
2020 $304 $224 $74–$624 $114
2021 $635 $352 $106–$1,054 $132
2022 $568 $448 $129–$1,270 $149
2023 $541 $533 $150–$1,390 $160
2024 $762 $605 $160–$1,606 $164
2025 $1,252 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $653 32 payments
  2. Ardelyx, Inc. $443 16 payments
  3. Nestle HealthCare Nutrition Inc. $357 20 payments
  4. RedHill Biopharma Inc. $341 22 payments
  5. Braintree Laboratories, Inc. $330 11 payments
  6. AbbVie, Inc. $326 15 payments
  7. Aimmune Therapeutics, Inc. $224 12 payments
  8. Allergan Inc. $214 17 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $200 8 payments
  10. Intercept Pharmaceuticals, Inc. $185 8 payments
  11. Other $1,262 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,417 206 payments
  2. Education $118 3 payments
Products named General payments · program years 2019–2025
  1. ZENPEP $580 32 payments
  2. STELARA $469 22 payments
  3. IBSRELA $443 16 payments
  4. TREMFYA $415 22 payments
  5. Talicia $333 21 payments
  6. SIMPONI ARIA $328 15 payments
  7. SIMPONI $328 15 payments
  8. SUTAB $255 7 payments
  9. LINZESS $251 23 payments
  10. CREON $157 8 payments
  11. Other $2,097 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

669

Median for Gastroenterology: 569

Drug cost

$311,652

Median for Gastroenterology: $104,976

Branded share of claims

57.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 42 $179,593
Humira(Cf) Pen Adalimumab Brand 13 $85,777
Mesalamine Generic 91 $26,405
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 50 $5,757
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 31 $5,005
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 203 $3,358
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 19 $2,478
Omeprazole Generic 101 $1,026
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 13 $795
Esomeprazole Magnesium Generic 12 $513

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$56,769

Medicare's payments for the services billed

Medicare patients

242

Average age 73

Services billed

493

158 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 54%
Diabetes 36%
Depression 35%
Osteoporosis 31%
Ischemic heart disease 24%
Chronic kidney disease 11%
Cancer 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $120
$120 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $118
$118 42 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $98
$98 — —
IBSRELA
  • Ardelyx, Inc. $86
$86 — —
Talicia
  • RedHill Biopharma Inc. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record